What one share of Autolus Therapeutics holds
We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells.
Autolus Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.44 |
|---|---|
| Profit | −$1.05 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$0.87 |
| Cash and investments | $0.64 |
| Book value | $0.28 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.12 | −$1.26 | $0.19 | −$1.18 | — | $3.09 |
| 2017 | $0.12 | −$1.43 | $0.21 | −$1.40 | — | $10.35 |
| 2018 | $0.04 | −$1.42 | $0.29 | −$1.29 | — | $6.36 |
| 2019 | $0.07 | −$2.88 | $0.43 | −$2.78 | — | $5.67 |
| 2020 | — | −$2.76 | $0.28 | −$2.57 | — | $4.01 |
| 2021 | — | −$1.97 | $0.12 | −$1.76 | — | $3.45 |
| 2022 | — | −$1.57 | $0.11 | −$1.30 | — | $1.73 |
| 2023 | $0.01 | −$1.20 | $0.06 | −$0.90 | — | $0.42 |
| 2024 | $0.04 | −$0.86 | $0.09 | −$0.89 | — | $1.61 |
| 2025 | $0.28 | −$1.08 | $0.07 | −$1.14 | — | $0.67 |
Common questions about Autolus Therapeutics
How much does one share of Autolus Therapeutics earn?
Over the last 12 months, Autolus Therapeutics lost $1.05 for each share on $0.44 of sales.
Does Autolus Therapeutics pay a dividend?
Autolus Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Autolus Therapeutics’s book value per share?
Autolus Therapeutics’s book value is $0.28 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Autolus Therapeutics have?
Each share of Autolus Therapeutics has $0.64 of cash and investments, as of June 30, 2026.
What is Autolus Therapeutics’s free cash flow per share?
−$0.87 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Autolus Therapeutics bought back shares?
Autolus Therapeutics’s share count rose about 2579% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.